Antibodies News and Research

RSS

Self-assembling nanoparticles as a way towards next-generation COVID-19 vaccines

In a promising study by US researchers, the receptor-binding domain (RBD) and stabilized spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were displayed on nanoparticles as vaccine antigens and elicited potent immune responses.

16 Sep 2020

Candidate monoclonal antibody shows hope as COVID-19 treatment

Researchers in the United States have described the effectiveness of a candidate monoclonal antibody currently being evaluated in a Phase 1 trial as a therapy for coronavirus disease 2019 (COVID-19) and its causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

16 Sep 2020

Carotid artery calcification seen in radiographs linked with coronary artery disease, oral infections

The calcification of the carotid artery is a sign of advanced arteriosclerosis, which may be associated with chronic coronary artery disease (CAD) and can lead to death. Such calcification can be seen in regular oral panoramic radiography.

16 Sep 2020

Sub-Saharan Africa needs greater access to live-saving antibodies

Sub-Saharan Africa must increase access to live-saving, laboratory-produced antibodies, writes Yolanda Moyo.

16 Sep 2020

Critical insights into COVID-19 exposure for healthcare workers

A recent Northwestern University Feinberg School of Medicine study published in the preprint server medRxiv in September 2020 shows that the use of standard guidelines of infection control, including personal protective equipment (PPE), helps to prevent the undue risk of infection among HCWs as well.

16 Sep 2020

Study highlights role of specific protein in the mass production of antibodies

Antibodies play a fundamental role in medicine, and antibody-mediated immune response is the ultimate target in the quest for a vaccine to defeat the current pandemic.

16 Sep 2020

Researchers are testing the effectiveness of multiple treatments to prevent COVID-19

A study on the effectiveness of multiple treatments, including laboratory-made antibodies, at preventing mild COVID-19 from advancing to severe illness in the outpatient setting is underway by researchers at The University of Texas Health Science Center at Houston (UTHealth).

16 Sep 2020

SARS-CoV-2 infection severity linked to superior humoral immunity against the S-protein

In a recent bioRxiv* preprint paper, Jenna J. Guthmiller et al., focus on the acute infection of SARS-CoV-2 and observe that the humoral immunity is distinctive with the infection stage and viral antigens.

16 Sep 2020

Patients with more severe SARS-CoV-2 infection exhibit larger antibody response

Researchers in the United States have found that individuals who develop more severe disease following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mount a larger antibody and memory B cell response during both acute infection and convalescence.

15 Sep 2020

Newly identified mechanism regulates the distensibility of the heart

A healthy heart beats 50 to 100 times a minute and pumps 8,000 litres of blood around our body every day. A precondition for this function is the elasticity of the cardiac walls, which dilate as blood flows in (diastole) and contract again as the blood flows out (systole).

15 Sep 2020

New antibody assay for COVID-19 promises sensitive mass-scale detection

A new paper by researchers at McMaster University and Hamilton Health Sciences, published on the preprint server medRxiv in September 2020, reports on the development of a serologic assay that is suitable for sensitive high-throughput antibody testing for COVID-19.

15 Sep 2020

Immunologists analyze types of immune response to predict an effective COVID-19 vaccine

Immune reactions caused by vaccination can help protect the organism, or sometimes may aggravate the condition.

15 Sep 2020

Bio-Rad launches StarBright Violet 515 Dye for use in flow cytometry

Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, today announced the launch of StarBright Violet 515 Dye, the first of a new range of unique fluorescent nanoparticles, for use in flow cytometry.

From Bio-Rad Laboratories 15 Sep 2020

3D printed nanoparticle biosensing platform detects SARS-CoV-2 antibodies within seconds

Pandemics caused by novel infectious agents like the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Zika, or Ebola virus seriously impact human health and lives while also overwhelming health care systems all over the world. Early detection and diagnosis allow isolation of the infected patients and contact tracing, which can mitigate the spread of the virus and save lives, especially when a significant number of the patients are asymptomatic.

14 Sep 2020

Central nervous system immune responses to COVID-19

A recent study published on the preprint server bioRxiv by scientists from Yale School of Medicine, University of California, Yale School of Public Health, Yale University, and Howard Hughes Medical Institute examined the impact of SARS-CoV-2 infection on the central nervous system.

14 Sep 2020

NIH and FDA examine serious side effect that surfaced in COVID vaccine trial

The Food and Drug Administration is weighing whether to follow British regulators in resuming a coronavirus vaccine trial that was halted when a participant suffered spinal cord damage, even as the National Institutes of Health has launched an investigation of the case.

14 Sep 2020

RUDN geneticist finds a bifidobacterial protein that can reduce inflammation in COVID-19

A geneticist from RUDN University studied the effect of Bifidobacterium (intestinal bacteria) on the inflammatory process and discovered that their surface protein is capable of stopping excessive or uncontrollable inflammation, like the one observed in COVID-19 patients.

14 Sep 2020

Oxford University and AstraZeneca resume COVID-19 vaccine trial

More than a hundred candidate vaccine trials against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease (COVID-19), are underway. About 35 are now undergoing clinical evaluation, and of these, nine are in the final phase of human trials, including the vaccine developed by Oxford University and the biopharmaceutical firm, AstraZeneca.

14 Sep 2020

Tiny antibody component shows high potency in SARS-CoV-2 animal models

University of Pittsburgh School of Medicine scientists have isolated the smallest biological molecule to date that completely and specifically neutralizes the SARS-CoV-2 virus, which is the cause of COVID-19.

14 Sep 2020

Toyonaka Municipal Hospital reports successful control of COVID-19

Researchers at Toyonaka Municipal Hospital in Japan have shown that the rate of subclinical infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among staff at the hospital is no higher than among the general population in the same area.

14 Sep 2020